Apellis Pharmaceuticals Files 8-K on Shareholder Votes
Ticker: APLS · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1492422
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
Related Tickers: APLS
TL;DR
APLS filed an 8-K for shareholder votes on 6/5/24.
AI Summary
Apellis Pharmaceuticals, Inc. filed an 8-K on June 5, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the votes or resolutions presented to shareholders, but it serves as an official record of the company's corporate governance activities.
Why It Matters
This filing indicates that Apellis Pharmaceuticals held a meeting where security holders voted on certain matters, which is a standard part of corporate governance and transparency.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure regarding shareholder votes and does not contain material financial or operational information that would immediately impact the company's risk profile.
Key Players & Entities
- Apellis Pharmaceuticals, Inc. (company) — Registrant
- June 5, 2024 (date) — Date of Report
- 001-38276 (other) — SEC File Number
- 100 Fifth Avenue Waltham, MA 02451 (address) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of Apellis Pharmaceuticals' security holders on June 5, 2024?
The provided text of the 8-K filing does not specify the exact matters that were submitted to a vote of security holders.
What is the SEC file number for Apellis Pharmaceuticals?
The SEC file number for Apellis Pharmaceuticals, Inc. is 001-38276.
Where are Apellis Pharmaceuticals' principal executive offices located?
Apellis Pharmaceuticals' principal executive offices are located at 100 Fifth Avenue, Waltham, MA 02451.
What is the standard industrial classification for Apellis Pharmaceuticals?
The standard industrial classification for Apellis Pharmaceuticals is PHARMACEUTICAL PREPARATIONS [2834].
What is the fiscal year end for Apellis Pharmaceuticals?
The fiscal year end for Apellis Pharmaceuticals is December 31 (1231).
Filing Stats: 556 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2024-06-05 16:50:00
Filing Documents
- d816010d8k.htm (8-K) — 31KB
- 0001193125-24-155179.txt ( ) — 147KB
- apls-20240605.xsd (EX-101.SCH) — 3KB
- apls-20240605_lab.xml (EX-101.LAB) — 17KB
- apls-20240605_pre.xml (EX-101.PRE) — 11KB
- d816010d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Apellis Pharmaceuticals, Inc. Date: June 5, 2024 By: /s/ Timothy Sullivan Timothy Sullivan Chief Financial Officer